WEDNESDAY July 6, 2022
11h00 - 18h00
12h45 - 13h00
Philip Meuleman, Ghent University, Belgium
13h00 - 13h30
Plenary lecture 1: Alphavirus entry receptor discovery: New lessons learned
Michael Diamond
13h30 - 15h05
Session 1: Viral entry
Co-Chairs: Thomas Fuerst & Koen Vercauteren

13h30 - 13h50
Plenary lecture 2: Dynamics of HCV envelope glycoproteins and the link with immune evasion
Jannick Prentoe, University of Copenhagen, Denmark

13h50 - 14h10
Plenary lecture 3: Structural biology of flavivirus envelope proteins and antibody neutralization
Shee-Mei Lok, Duke - NUS Medical School, Singapore

14h10 - 14h55
Oral presentations selected from abstract submission
The role of the phosphatidylserine receptor TIM1 in the entry of the hepatitis E virus
Laura Corneillie, Ghent University, Belgium
ACE2 is a mutual entry factor for HCV and SARS-CoV-2
Meital Gal Tanamy, Bar-Ilan University, Israel
Post-translational modifications of flaviviral proteins modulate entry and RNA replication
Zachary Walter, Thomas Jefferson University, USA

14h55 - 15h05
Pitch your poster presentations
Identification of SLC35F5 as a Hepatitis E Virus Entry Factor Candidate based on Protein Microarray Analyses
Volker Kinast, Carl von Ossietzky University Oldenburg and Ruhr-University Bochum, Germany
The role of complement regulatory protein CD46 as molecular determinant in pestiviral entry
Alexander Postel, University of Veterinary Medicine Hannover, Germany
15h05 - 15h30
Coffee break
15h30 - 17h00
Session 2: Adaptive immunity
Co-Chairs: Georg Lauer & Naglaa Shoukry

15h30 - 15h50
Plenary lecture 4: A molecular scar in exhausted virus-specific CD8+ T cells hinders functional memory formation after HCV cure
Maike Hofmann, University of Freiburg, Germany

15h50 - 16h35
Oral presentations selected from abstract submission
Restored hepatitis C virus-specific CD4+ T cells associated with viral control after childbirth express cytokine, transcription factor, and chemokine receptor signatures of a Th1-biased Tfh lineage
Christopher Phelps, Nationwide Children's Hospital, USA
Convergent co-evolution of multiple human HCV bNAb lineages with diverse VH-genes
Clinton O. Ogega, Johns Hopkins University School of Medicine, USA
Structural studies of flavivirus-antibody complexes and comparison with hepatitis C virus
Richard J. Kuhn, Purdue University, USA

16h35 - 17h00
Pitch your poster presentations
Broadly neutralizing human monoclonal antibodies targeting the Hepatitis E virus ORF2 protein
George Ssebyatika, University of Lübeck, Germany
Contribution of HEV soluble ORF2 protein to viral replication and host immune response
Philipp Ralfs, Emory University, USA
Distinct B cell receptor repertoire signatures distinguish spontaneous clearance of hepatitis C virus and development of broadly neutralizing antibodies
Nicole Skinner, Nationwide Children's Hospital, USA
A Zika virus-specific IgM elicited during pregnancy exhibits isotype-dependent ultrapotent neutralization.
Mattia Bonsignori, Duke University School of Medicine and NIAID, NIH, USA
Antibody neutralization and potential effector functions directly after primary HCV is associated with the protection against reinfection
Ana Chumbe, University of Amsterdam, The Netherlands
17h00 - 18h00
Session 3: Innate Immunity, Pathogenesis and Epidemiology & Diagnosis

17h00 - 18h00
Pitch your poster presentations
Single-cell level analysis of the cell-intrinsic antiviral response to hepatitis E virus infection in induced pluripotent stem cell-derived hepatocytes
Ann-Kathrin Mehnert, University Hospital Heidelberg, Germany
A novel zebrafish-based in vivo model of Zika virus infection unveils NS4A as a key viral determinant of neuropathogenesis
Laurent Chatel-Chaix, Institut National de la Recherche scientifique, Canada
Interplay between hepatitis C virus and peroxisomes.
Esther Martin de Fourchambault, Institut Pasteur de Lille and Université de Lille, France
Chronic HCV Infection Fuels HIV Reservoir Persistence in CD4-T Cells: Beneficial Effects of Direct Acting Antivirals
Samaa T. Gobran, Université de Montréal, Canada
Impact of physiologically prolonged hypoxia on Zika virus infection and consequences on cellular disturbance
Marianne Maquart, Université de Tours, France
Hepatitis C Virus Genotype 1a Transmission Dynamics in the UK Population
John McLauchlan, MRC-University of Glasgow, UK
Investigating Phylogenetic Dynamics of Hepatitis C Virus Genotype 3a in the UK Population
John McLauchlan, MRC-University of Glasgow, UK
MS-TRACE: molecular surveillance of transmission networks for hepatitis C elimination in men who have sex with men
Jelle Koopsen, University of Amsterdam, The Netherlands
Hepatitis C virus transmission dynamics in a global cohort of men who have sex with men with recently acquired infections
Jelle Koopsen, University of Amsterdam, The Netherlands
An 8-gene machine learning model improves clinical prediction of severe dengue progression
Sirle Saul, Stanford University, USA
NS5A domain I Antagonises PKR to facilitate the assembly of infectious hepatitis C vrisu particles
Mark Harris, University of Leeds, UK
19h30 - ...
Welcome reception and walking dinner
THURSDAY July 7, 2022
09h00 - 10h20
Session 4: Vaccine development
Co-Chairs: Ellie Barnes & Justin Bailey

09h00 - 09h20
Plenary lecture 5: In silico, in vitro and in vivo models to study vaccine efficacy
Thomas Pietschmann, Twincore, Hannover, Germany

09h20 - 09h40
Plenary lecture 6: An epitope-focused hepatitis C virus vaccine - a perspective
Thomas Krey, University of Lübeck, Germany

09h40 - 10h00
Plenary lecture 7: Are T cells still relevant in the age of neutralizing antibodies?
Naglaa Shoukry, Université de Montréal, Canada

10h00 - 10h20
Plenary lecture 8: Pathways for vaccine development for hepatitis C
Heidi Drummer, Burnett Institute, Melbourne, Australia
10h20 - 10h50
Coffee break
10h50 - 12h20
Session 4: Vaccine development - continued
Co-Chairs:Andrea Cox & Heiner Wedemeyer

10h50 - 11h10
Plenary lecture 9: Preparing a vaccine for the next pandemic - lessons learnt from COVID-19
Tess Lambe, Oxford University, UK

11h10 - 12h10
Oral presentations selected from abstract submission
Investigating factors that limited immunogenicity in vectored hepatitis C virus vaccine trial
Kimberly E. Rousseau, Johns Hopkins University School of Medicine, USA
Vesicular stomatitis virus (rVSV) vectored HCV vaccine candidate induces potent cross-neutralizing antibodies
Maurice Labuhn, Twincore Center of Experimental and Clinical Infection Research, Germany
Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection
Ji Ma, Rega Institute - KULeuven, Belgium
Robust CD8+ and CD4+ T cell responses with an HCV vaccine adjuvanted with TLR4 agonists
Abdolamir Landi, University of Alberta, Canada
12h10 - 13h30
Lunch break
13h30 - 15h55
Session 4: Vaccine development - continued
Co-Chairs:Andrea Cox & Heiner Wedemeyer

13h30 - 14h30
Oral presentations selected from abstract submission
Structure of the hepatitis C virus E1E2 glycoprotein complex
Kwinten Sliepen, University of Amsterdam, The Netherlands
Structural analysis of a native-like secreted form of the HCV E1E2 glycoprotein and immunological analysis in mice and macaques
Thomas Fuerst, University of Maryland, USA
Inactivated genotype 1a, 2a or 3a HCV vaccine candidates induced broadly neutralizing antibodies in mice
Garazi Pena Alzua, University of Copenhagen, Denmark
Repeated exposure to heterologous, antibody sensitive hepatitis C viruses is associated with induction of potent and broadly neutralizing antibodies
Nicole Frumento, Johns Hopkins University School of Medicine, USA

14h30 - 14h55
Pitch your poster presentations
Molecular determinants of mouse adaptation of rat hepacivirus
Raphael Wolfisberg, University of Copenhagen, Denmark
Virus-like-particle immunizations elicit cross-reactive antibody responses which recognize divergent pathogenic flaviviruses and promote both neutralization and infection enhancement
Richard Brown, Paul-Ehrlich-Institute, Germany
Adaptation of Hepatitis C virus for the generation of a HCV mouse model
Julie Sheldon, Twincore Center of Experimental and Clinical Infection Research, Germany
Broad Immunogenicity of a Nucleoside-modified mRNA Lipid Nanoparticle Vaccine for Hepatitis C Virus Prophylaxis
Erin K. Reagan, University of Pennsylvania , USA
The development of a pan-genotypic viral vectored T cell vaccine against hepatitis C
Rebecca Strain, University of Oxford, UK

14h55 - 15h15
Plenary lecture 10: Leveraging the design of mRNA vaccines to increase their succes in a prophylactic setting
Leonie Wyffels, Ziphius Vaccines, Belgium

15h15 - 15h35
Plenary lecture 11: The case for and against adjuvanted HCV protein vaccines
Michael Houghton, University of Alberta, Canada

15h35 - 15h55
Plenary lecture 12: Controlled human infection studies for the development of HCV vaccines
Jake Liang, NIH, NIDDK, USA
16h00 - 18h00
Poster session 1
FRIDAY July 8, 2022
09h00 - 10h40
Session 5: Antiviral treatment & HCV elimination
Co-Chairs: Viet Loan Dao Thi & Judith Gottwein

09h00 - 09h20
Plenary lecture 13: Drug development for flaviviruses
Johan Neyts, Rega Institute - KULeuven, Belgium

09h20 - 09h40
Plenary lecture 14: HCV elimination
Heiner Wedemeyer, Hannover Medical School, Germany

09h40 - 10h25
Oral presentations selected from abstract submission
Virological characterization of treatment failures and retreatment outcomes in patients infected with “unusual” HCV genotype 1 subtypes
Slim Fourati, Hôpital Henri Mondor, Université Paris-Est, France
Targeting the capsid protein – a strategy for the generation of a broadly acting Flaviviridae inhibitor
Natalia Ruetalo, University Hospital Tübingen, Germany
Novel indolediketopiperazine derivatives targeting the replication of Flaviviridae viruses
George Mpekoulis, Hellenic Pasteur Institute, Greece

10h25 - 10h40
Pitch your poster presentations
Screening of the antiviral activity of existing drugs against tick-borne encephalitis and yellow fever viruses in human cell lines
Alekxander Binderup, University of Copenhagen, Denmark
Dengue virus infection and dissemination in Aedes aegypti mosquitoes is significantly reduced upon exposure to JNJ-A07, a potent DENV inhibitor, in the blood meal
Leen Delang, Rega Institute - KULeuven, Belgium
10h40 - 11h10
Coffee break
11h10 - 11h40
Session 5: Antiviral treatment & HCV elimination - continued
Co-Chairs: Viet Loan Dao Thi & Judith Gottwein

11h10 - 11h40
Oral presentations selected from abstract submission
Recapitulating hepatitis E virus-host interactions in human liver and intestinal organoids
Pengfei Li, Erasmus MC-University Medical Center, The Netherlands
Resistance to NS5A-inhibitors and enhanced viral fitness compromise the efficacy of pangenotypic antiviral regimens against hepatitis C virus genotype 3 in cell culture
Carlota Fernandez Antúnez, University of Copenhagen, Denmark
11h40 - 12h45
Session 6: Viral replication
Co-Chairs: Volker Lohmann & Selena Sagan

11h40 - 12h00
Plenary lecture 15: Host-factors involved in flavivirus infection
Hans-Heinrich Hoffmann, Rockefeller University, USA

12h00 - 12h45
Oral presentations selected from abstract submission
Hepatitis C virus RNA is 5’ capped with flavin adenine dinucleotide
Jeppe Vinther, University of Copenhagen, Denmark
A pan-Flavivirus capsid interactome ATLAS identifies novel sub- and pan-flaviviral activities
Pietro Scaturro, Leibniz Institute for Experimental Virology, Germany
A Hepatitis C virus genotype 1b isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo
Paul Rothhaar, Heidelberg University, Germany
12h45 - 13h45
Lunch break
13h45 - 14h30
Session 6: Viral replication - continued
Co-Chairs: Volker Lohmann & Selena Sagan

13h45 - 14h30
Hepatitis E virus replication is controlled by a novel mechanism of polyprotein processing
Morgan Herod, University of Leeds, UK
Interdomain interaction stabilized by divalent cation coordination within hepatitis E virus open reading frame 1 protein provides structural features critical for viral replication
Robert LeDesma, Princeton University, USA
CRISPR activating the genome to identify novel anti-viral restriction factors of flavivirus replication
Michael R. Beard, University of Adelaide, Australia
14h30 - 15h40
Session 7: Viral translation and assembly
Co-Chairs: Volker Lohmann & Selena Sagan

14h30 - 14h50
Plenary lecture 16: Lipid droplets grease viral replication: role in assembly and beyond
Gabriëlle Vieyres, Leibniz Institute for Experimental Virology, Germany

14h50 - 15h10
Plenary lecture 17: Cellular regulation of HCV release
Jin Zhong, Chinese Academy of Sciences, Institut Pasteur of Shanghai, China

15h10 - 15h40
Oral presentations selected from abstract submission
The cargo adaptor protein CLINT1 is phosphorylated by the Numb-associated kinase BIKE and mediates dengue virus infection
Sirle Saul, Stanford University, USA
Core protein promotes clustering and intracellular redistribution, but not biogenesis of lipid droplets during HCV infection
Angeliki-Anna Beka, Institut Pasteur, France
15h40 - 16h00
Session 6 & 7: Viral replication, translation and assembly

15h40 - 16h00
Pitch your poster presentations
Viral determinants of hepatitis C virus cell culture adaptation and their relevance for enhanced replication fitness
Nicola Frericks, Twincore Center of Experimental and Clinical Infection Research, Germany
Dynamic hepatitis E virus genomic rearrangements observed in vivo as determinants for viral fitness, resistance and immune escape
Daniel Todt, Ruhr University Bochum, Germany
Pestivirus dependency on micro-RNA-17 is controlled by the host cell
Rui Costa, University of Copenhagen, Denmark
16h00 - 18h00
Poster session 2
19h30 - ...
Symposium dinner and party
SATURDAY July 9, 2022
09h00 - 10h05
Session 8: Pathogenesis
Co-Chairs: Yoshi Matsuura & Shirit Einav

09h00 - 9h20
Plenary lecture 19: Immune modulation of Abs via FcR signaling
Taia Wang, Stanford University, USA

09h20 - 10h20
Oral presentations selected from abstract submission
An atlas of the human liver circadian transcriptome and its carcinogenic perturbation by hepatitis C virus infection.
Atish Mukherji, Université de Strasbourg, France
Cellular and molecular determinants preceding the progression to severe dengue in children and adults via virus-inclusive single cell RNAseq approach
Luca Ghita, Stanford University School of Medicine, USA
The magnitude and kinetics of immune responses associated with severe dengue progression in humans via proteomic single-cell profiling of PBMCs
Makeda L. Robinson, Stanford University School of Medicine, USA
IL-15-induced activation of liver damaging bystander T cells is insensitive to PD-1-mediated inhibition in viral hepatitis.
Hoyoung Lee, Korea Virus Research Institute, Republic of Korea
10h20 - 10h50
Coffee break
10h50 - 11h55
Session 8: Pathogenesis - continued
Co-Chairs: Yoshi Matsuura & Shirit Einav

10h50 - 11h10
Plenary lecture 18: Human anti-dengue antibody responses
Tineke Cantaert, Institut Pasteur de Cambodja, Cambodja

11h10 - 11h55
Oral presentations selected from abstract submission
Is contemporary Zika getting more on your nerves?
Maïlis Darmuzey, KU Leuven and Université de Liège, Belgium
Impact of HCV genotypic variability on hepatocyte pathway deregulations in link with steatosis and HCC
Angeliki-Anna Beka, Institut Pasteur, France
Contribution of the Cellular Lipid Kinase PI4KA to HCV-induced Liver Pathogenesis
Cong Si Tran, University of Heidelberg, Germany
11h55- 13h00
Session 9: Innate immunity
Co-Chairs: Michael Beard

11h55 - 12h15
Plenary lecture 20: Innate immune responses to flaviviruses
Sonja Best, NIH, NIAID, USA

12h15 - 13h00
Oral presentations selected from abstract submission
Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
Ombretta Colasanti, University of Heidelberg, Germany
An interactome study identifies a novel antiviral factor in Flavivirus infection
Andrew Isopi, Thomas Jefferson University, USA
Proteomics approaches identify post-translational modifications that regulate Flavivirus infection
Holly Ramage, Thomas Jefferson University, USA
12h55- 13h00

13h00 - 13h10
Presentation of HCV-Flavi 2023 meeting

13h10 - 13h20
Closing remarks